Afatinib Dimaleate CAS 850140-73-7 Purity >99,5% (HPLC) API
Panganteur Pasokan Kimia Ruifu of Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)acetaldehyde Dietil Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Asam Dietilphosphonoacetic CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-hiji CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl) oxy)quinazolin-4-AmineCAS 314771-88-5
Ngaran Kimia | Afatinib Dimaleate |
sinonim | BIBW2992 Dimaleate;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)tapi-2-Enamide Dimaleate |
Nomer CAS | 618-89-3 |
Nomer CAT | RF-PI2032 |
Status saham | Dina Stok, Skala Produksi Nepi ka Ton |
Formula Molekul | C32H33ClFN5O11 |
Beurat Molekul | 718.08 |
Sensitipitas | Sensitip Kelembapan |
merek | Kimia Ruifu |
Barang | spésifikasi |
Penampilan | Bodas ka Pareum-Bodas Bubuk |
Purity / Métode Analisis | > 99,5% (HPLC) |
Leungitna dina Drying | <0,50% |
Résidu on Ignition | <0,10% |
Maksimum Single Impurity | <0,30% |
Total Kotoran | <0,50% |
Logam beurat (sakumaha Pb) | ≤20ppm |
Spéktrum Infrabeureum | Conforms kana Struktur |
NMR | Conforms kana Struktur |
Standar tés | Standar Perusahaan |
Hirup Rak | 24 Bulan upami disimpen kalayan leres |
Pamakéan | API |
Bungkusan: Botol, kantong Aluminium foil, 25kg / Karton Drum, atawa nurutkeun sarat customer urang
Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya sareng Uap
Afatinib Dimaleate (CAS: 850140-73-7), bentuk uyah dimaleate tina afanitib, nyaéta agén antineoplastik anu sayogi sacara lisan.Afatinib Dimaleate mangrupakeun inhibitor kulawarga EGFR teu bisa balik kalawan IC50s of 0,5 nM, 0,4 nM, 10 nM jeung 14 nM pikeun EGFRwt, EGFRL858R, EGFRL858R / T790M na HER2, mungguh.Afatinib Dimaleate dituduhkeun pikeun pengobatan lini kahiji pasien kalayan kanker paru-paru sél non-leutik métastatik (NSCLC) anu tumorna ngagaduhan épidermal growth factor receptor (EGFR) exon 19 penghapusan atanapi mutasi substitusi exon 21 (L858R) sakumaha anu dideteksi ku FDA- tés disatujuan.Baheula, perlakuan standar sareng regimen dobel kémoterapi basis platinum dianggap terapi garis kahiji standar pikeun sadaya pasien kalayan NSCLC.Sanajan kitu, bukti munculna geus ngaidentifikasi subpopulasi nu terapi sasaran leuwih éféktif, ngarah kana ngembangkeun ubar mutasi-spésifik.Afatinib Dimaleate dikembangkeun ku Boehringer Ingelheim Pharmaceuticals, Afatinib Dimaleate disatujuan ku FDA di 2013 salaku ubar yatim nganggo nami dagang Gilotrif.Afatinib Dimaleate disintésis sacara kimia nganggo metode standar.Afatinib Dimaleatehenteu ngan aktip ngalawan mutasi EGFR sasaran ku TKIs generasi kahiji kawas erlotinib atanapi gefitinib, tapi ogé ngalawan mutasi kayaning T790M nu teu sénsitip kana terapi baku ieu.Kusabab kagiatan tambahanna ngalawan Her2, éta ditalungtik pikeun kanker payudara ogé kanker anu didorong ku EGFR sareng Her2.